NEW YORK (GenomeWeb) – Quanterix today announced a strategic investment in ImmunArray, a move that could strengthen each company's efforts in addressing neurodegenerative disease diagnostics.

Under the terms of the agreement, Lexington, Massachusetts-based Quanterix will gain access to ImmunArray's biomarker portfolio for traumatic brain injury and add select biomarkers to its multiplex panel for neurology research. ImmunArray, based in both Israel and Virginia, will in turn gain access to Quantertix's Simoa single-molecule array technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Dog DNA testing finds that some purebreds might not truly be purebreds, Inside Edition reports.

Mary Beckerle has returned as director of the Huntsman Cancer Institute, according to ScienceInsider.

Smithsonian Magazine reports that environmental DNA sampling can be used to track elusive organisms.

In Genome Research this week: repetitive satellite DNA in the fruit fly, transcriptome map assembly pipeline, and more.